Ingevity Corp (NGVT) stock
NGVTNYSEChemicals & Allied ProductsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3077% above fair value
$60.02−1.70 (-2.75%)
Close on Nov 16, 2026Market cap $2.06BP/E 40.8Yield –
Ingevity total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Ingevity's total debt was $1.20B at Jun 30, 2026. For fiscal 2025 it was $1.21B, down 13.7% from the year before. Over ten years it grew 29.7% a year on average. The highest annual figure on record is $1.47B in fiscal 2022.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.21B | -13.7% |
| FY2024 | Dec 31, 2024 | $1.40B | -4.5% |
| FY2023 | Dec 31, 2023 | $1.47B | -0.4% |
| FY2022 | Dec 31, 2022 | $1.47B | +16.1% |
| FY2021 | Dec 31, 2021 | $1.27B | -1.8% |
| FY2020 | Dec 31, 2020 | $1.29B | +3.4% |
| FY2019 | Dec 31, 2019 | $1.25B | +66.3% |
| FY2018 | Dec 31, 2018 | $752.40M | +65.9% |
| FY2017 | Dec 31, 2017 | $453.40M | -7.2% |
| FY2016 | Dec 31, 2016 | $488.80M | +446.8% |
| FY2015 | Dec 31, 2015 | $89.40M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.20B | -9.8% |
| Q1 FY2026 | Mar 31, 2026 | $1.20B | -13.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.21B | -13.7% |
| Q3 FY2025 | Sep 30, 2025 | $1.26B | -15.9% |
| Q2 FY2025 | Jun 30, 2025 | $1.33B | -11.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.39B | -6.7% |
| Q4 FY2024 | Dec 31, 2024 | $1.40B | -4.5% |
| Q3 FY2024 | Sep 30, 2024 | $1.50B | +1.7% |
| Q2 FY2024 | Jun 30, 2024 | $1.50B | -1.5% |
| Q1 FY2024 | Mar 31, 2024 | $1.49B | -0.7% |
| Q4 FY2023 | Dec 31, 2023 | $1.47B | -0.4% |
| Q3 FY2023 | Sep 30, 2023 | $1.47B | +27.6% |
| Q2 FY2023 | Jun 30, 2023 | $1.53B | +29.7% |
| Q1 FY2023 | Mar 31, 2023 | $1.50B | +18.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.47B | +16.1% |
| Q3 FY2022 | Sep 30, 2022 | $1.15B | -9.4% |
| Q2 FY2022 | Jun 30, 2022 | $1.18B | -7.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.27B | -1.4% |
| Q4 FY2021 | Dec 31, 2021 | $1.27B | -1.8% |
| Q3 FY2021 | Sep 30, 2021 | $1.27B | -2.0% |
| Q2 FY2021 | Jun 30, 2021 | $1.28B | -3.9% |
| Q1 FY2021 | Mar 31, 2021 | $1.28B | -13.9% |
| Q4 FY2020 | Dec 31, 2020 | $1.29B | +3.4% |
| Q3 FY2020 | Sep 30, 2020 | $1.30B | -1.3% |
| Q2 FY2020 | Jun 30, 2020 | $1.33B | -4.0% |
| Q1 FY2020 | Mar 31, 2020 | $1.49B | +4.8% |
| Q4 FY2019 | Dec 31, 2019 | $1.25B | +66.3% |
| Q3 FY2019 | Sep 30, 2019 | $1.32B | +75.9% |
| Q2 FY2019 | Jun 30, 2019 | $1.39B | +85.2% |
| Q1 FY2019 | Mar 31, 2019 | $1.42B | +90.0% |
| Q4 FY2018 | Dec 31, 2018 | $752.40M | +65.9% |
| Q3 FY2018 | Sep 30, 2018 | $748.90M | +65.2% |
| Q2 FY2018 | Jun 30, 2018 | $748.30M | +56.4% |
| Q1 FY2018 | Mar 31, 2018 | $748.00M | +49.0% |
| Q4 FY2017 | Dec 31, 2017 | $453.40M | -7.2% |
| Q3 FY2017 | Sep 30, 2017 | $453.40M | -12.6% |
| Q2 FY2017 | Jun 30, 2017 | $478.50M | – |
| Q1 FY2017 | Mar 31, 2017 | $502.10M | – |
| Q4 FY2016 | Dec 31, 2016 | $488.80M | – |
| Q3 FY2016 | Sep 30, 2016 | $518.50M | – |
See a number that looks wrong?